CA2966336A1 - Use of compositions modulating chromatin structure for graft versus host disease (gvhd) - Google Patents

Use of compositions modulating chromatin structure for graft versus host disease (gvhd) Download PDF

Info

Publication number
CA2966336A1
CA2966336A1 CA2966336A CA2966336A CA2966336A1 CA 2966336 A1 CA2966336 A1 CA 2966336A1 CA 2966336 A CA2966336 A CA 2966336A CA 2966336 A CA2966336 A CA 2966336A CA 2966336 A1 CA2966336 A1 CA 2966336A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
certain embodiments
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2966336A
Other languages
English (en)
French (fr)
Inventor
James E. Bradner
Bruce Blazar
Ryan Flynn
Jun Qi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Minnesota System
Original Assignee
Dana Farber Cancer Institute Inc
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, University of Minnesota System filed Critical Dana Farber Cancer Institute Inc
Publication of CA2966336A1 publication Critical patent/CA2966336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2966336A 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (gvhd) Abandoned CA2966336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076358P 2014-11-06 2014-11-06
US62/076,358 2014-11-06
PCT/US2015/059551 WO2016073903A1 (en) 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (gvhd)

Publications (1)

Publication Number Publication Date
CA2966336A1 true CA2966336A1 (en) 2016-05-12

Family

ID=55909890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2966336A Abandoned CA2966336A1 (en) 2014-11-06 2015-11-06 Use of compositions modulating chromatin structure for graft versus host disease (gvhd)

Country Status (9)

Country Link
US (1) US20190000860A1 (enExample)
EP (1) EP3215160A4 (enExample)
JP (1) JP2017533922A (enExample)
KR (1) KR20170098808A (enExample)
CN (1) CN107249593A (enExample)
AU (1) AU2015342895A1 (enExample)
BR (1) BR112017009440A2 (enExample)
CA (1) CA2966336A1 (enExample)
WO (1) WO2016073903A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038337B1 (ru) 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2016073956A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
JP6890097B2 (ja) * 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
US10633371B2 (en) 2016-04-22 2020-04-28 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
PT3746446T (pt) 2018-01-31 2022-07-18 Mirati Therapeutics Inc Inibidores de prc2
CN108685880A (zh) * 2018-04-16 2018-10-23 广东省人民医院(广东省医学科学院) Bcl-6小分子抑制剂用于制备预防或治疗cGVHD的药物
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
JP2022514353A (ja) * 2018-12-21 2022-02-10 ザ ウォルター アンド イライザ ホール インスティテュート オブ メディカル リサーチ 炎症の治療方法
EP3959214A1 (en) 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
CN112341390B (zh) * 2019-08-07 2022-08-23 四川大学 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
AU2023262308A1 (en) 2022-04-27 2024-10-03 Astrazeneca Uk Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
IL317937A (en) * 2022-08-09 2025-02-01 Dana Farber Cancer Inst Inc Macrocyclic BCL6 joints
WO2024211684A1 (en) * 2023-04-06 2024-10-10 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2250154T3 (es) * 1999-07-16 2006-04-16 Kissei Pharmaceutical Co., Ltd. Agentes que inhiben las reacciones de rechazo cronico despues de un transplante de organo.
WO2008066887A2 (en) * 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
KR20080107050A (ko) * 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
US20120014979A1 (en) * 2010-07-16 2012-01-19 Alexander Dent Use of bcl6 inhibitors for treating autoimmune diseases
AU2012223448B2 (en) * 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2013039988A1 (en) * 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
US9242962B2 (en) * 2011-11-04 2016-01-26 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013123521A1 (en) * 2012-02-17 2013-08-22 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2

Also Published As

Publication number Publication date
BR112017009440A2 (pt) 2017-12-19
KR20170098808A (ko) 2017-08-30
AU2015342895A1 (en) 2017-05-18
WO2016073903A1 (en) 2016-05-12
US20190000860A1 (en) 2019-01-03
CN107249593A (zh) 2017-10-13
EP3215160A1 (en) 2017-09-13
JP2017533922A (ja) 2017-11-16
EP3215160A4 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
CA2966336A1 (en) Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
AU2017363307B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
CA3012078C (en) Selective estrogen receptor degraders and uses thereof
CA2737219C (en) Halofuginone analogs for inhibition of trna synthetases and uses thereof
CA3069181A1 (en) Compounds for tau protein degradation
CA2897942A1 (en) Ras inhibitors and uses thereof
EP4003319A2 (en) Hdac6 inhibitors and uses thereof
JP2019537599A (ja) Ｍａｌｔ１分解のための化合物
CA2843853A1 (en) Macrocyclic insulin-degrading enzyme (ide) inhibitors and uses thereof
CA2964629A1 (en) Ezh2 inhibitors and uses thereof
CA3132387A1 (en) Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
AU2018342105B2 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
CA3019182A1 (en) Hck as a therapeutic target in myd88 mutated diseases
CA3157331A1 (en) A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
CA3012846A1 (en) Max binders as myc modulators and uses thereof
CA3143508A1 (en) Hck degraders and uses thereof
CN111566113B (zh) 大环化合物及其用途
CA3101553A1 (en) Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
US20230192679A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
CA3156546A1 (en) Substituted [1,2,4]triazolo-[4,3-c]pyrimidine compounds and use thereof as eed inhibitors
WO2019196953A1 (en) Ntcp inhibitors
CA3106548A1 (en) Histone demethylase 5 inhibitors and uses thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
WO2025179653A1 (en) Non-ubiquitin target protein degrader nutac and uses thereof
WO2019120200A1 (zh) 一类喹啉衍生物及其用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831